Ferroptosis is particularly significant in the luminal androgen receptor (LAR) subtype of triple-negative breast cancer, where GPX4 inhibitors combined with immunotherapy hold potential as a novel treatment strategy (16). Here, GPX4 is linked to triple-negative breast carcinoma.